| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Beta-1 adrenergic receptor |
|---|
| Ligand | BDBM50092021 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEBML_37262 |
|---|
| IC50 | 5600±n/a nM |
|---|
| Citation |  Brockunier, LL; Parmee, ER; Ok, HO; Candelore, MR; Cascieri, MA; Colwell, LF; Deng, L; Feeney, WP; Forrest, MJ; Hom, GJ; MacIntyre, DE; Tota, L; Wyvratt, MJ; Fisher, MH; Weber, AE Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides. Bioorg Med Chem Lett10:2111-4 (2000) [PubMed] |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Beta-1 adrenergic receptor |
|---|
| Name: | Beta-1 adrenergic receptor |
|---|
| Synonyms: | ADRB1 | ADRB1R | ADRB1_HUMAN | B1AR | Beta-1 adrenoceptor | Beta-1 adrenoreceptor | adrenergic Beta1 |
|---|
| Type: | G Protein-Coupled Receptor (GPCR) |
|---|
| Mol. Mass.: | 51338.40 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P08588 |
|---|
| Residue: | 477 |
|---|
| Sequence: | MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG
MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV
WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC
TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM
AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP
LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV
FFNWLGYANSAFNPIIYCRSPDFRKAFQGLLCCARRAARRRHATHGDRPRASGCLARPGP
PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV
|
|
|
|---|
| BDBM50092021 |
|---|
| n/a |
|---|
| Name | BDBM50092021 |
|---|
| Synonyms: | 4-[4-(3-Fluoro-4-methoxy-phenyl)-[1,2,3]triazol-2-yl]-N-{4-[2-((R)-2-hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-benzenesulfonamide | CHEMBL63357 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C30H29FN6O4S |
|---|
| Mol. Mass. | 588.652 |
|---|
| SMILES | COc1ccc(cc1F)-c1cnn(n1)-c1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1 |
|---|
| Structure | 
|
|---|
Search and Browse
